Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 7/20 | 0.48 |
| ▸ | MMP9 | P14780 | 7/20 | 0.48 |
| ▸ | MMP8 | P22894 | 7/20 | 0.48 |
| ▸ | MMP13 | P45452 | 7/20 | 0.48 |
| ▸ | CHEK2 | O96017 | 7/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1453961 | 0.75 | NAMPT (0.46) | TP53MAPT | |
| SCHEMBL19753933 | 0.74 | TP53 (0.61) | MMP2MMP9MMP8MMP13CHEK2 | |
| SCHEMBL810440 | 0.73 | CHEK2 (0.56) | MMP2MMP9MMP8MMP13CHEK2 | |
| SCHEMBL30045266 | 0.72 | MAPT (0.51) | MMP2MMP9MMP8MMP13TP53 | |
| SCHEMBL19739092 | 0.72 | SMN1; SMN2 (0.50) | TP53MAPTSMN1; SMN2HPSE | |
| SCHEMBL1455827 | 0.71 | NAMPT (0.47) | TP53MAPTSMN1; SMN2 | |
| SCHEMBL1454630 | 0.71 | RAB9A (0.47) | TP53MAPTSMN1; SMN2 | |
| SCHEMBL1455538 | 0.70 | USP2 (0.60) | MAPTSMN1; SMN2MAP4K4 | |
| SCHEMBL31483499 | 0.70 | ALDH1A1 (0.52) | SMN1; SMN2 | |
| SCHEMBL14444778 | 0.69 | KDR (0.72) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971611-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2012-10-10 | — | — | EP | disclosed |
| EP-2345652-A1 | Antiviral compounds | Abbott Laboratories (US) | 2011-07-20 | — | — | EP | disclosed |
| US-7915411-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2011-03-29 | — | — | US | disclosed |
| EP-1971611-A1 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007081517-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | MMP2 3760/4885MMP9 2320/4885MMP8 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.